FibroBiologics (FBLG) and Charles River Laboratories (CRL) established a master services agreement to develop and manufacture FibroBiologics’ therapeutic master cell bank, working cell bank, and fibroblast-based spheroids product, CYWC628, for utilization in a diabetic foot ulcer, DFU, clinical trial slated to begin in 2025. “The formalization of our working relationship with Charles River is a pivotal step as we advance toward a significant wound care clinical trial in 2025 with CYWC628,” said Pete O’Heeron, Founder and Chief Executive Officer of FibroBiologics. “Working with Charles River opens new possibilities for innovation with its global reach and scalability potential. By combining our unique therapeutic fibroblast-based spheroids approach with Charles River’s expertise and unparalleled support, we are positioned to accelerate progress in delivering this treatment to patients.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FBLG:
- FibroBiologics issued patent for fibroblast delivery of tumor inhibitory agents
- Maxim starts FibroBiologics at Buy, sees fibroblast therapy as ‘more potent’
- FibroBiologics initiated with a Buy at Maxim
- FibroBiologics engages Southern Star Research as CRO in Australia
- FibroBiologics files patent application for fibroblast cell-based technology